There are 15,358 results relating to "Medicin Viagra-m"
Order by
|
Questions and Answers
Date answered:
1 July 2021
S6W-00949
These reports have also been reviewed by independent experts of the Commission on Human Medicines’ COVID-19 Vaccines Benefit Risk Expert Working Group and members of its Medicines for Women’s Health Expert Advisory Group.
Questions and Answers
Date answered:
30 March 2022
S6W-07401
Regulation for the licensing, safety and efficacy of medicines is reserved to the UK Government and is the responsibility of the UK’s independent medicines regulator the Medicines and Healthcare products Regulatory Agency (MHRA).
Official Report
Meeting date:
29 January 2025
Public Audit Committee 29 January 2025
We have focused on moving from branded to generic medicines, and we are looking at polypharmacy and reducing the number of medicines that we prescribe to people.
Committee reports
Date published:
19 May 2020
Annual Report of the Health and Sport Committee for 2019-20 - Inquiries and reports
We have also initiated inquiries into—
Social prescribing of physical activity and sport;
The supply and demand for medicines;
Social care; and
COVID-19.
Last updated:
26 January 2026
BB20260127
Members are advised to lodge amendments in good time before the beginning of a Stage and as early as possible during the day. (G) = Government Bill; (M) = Member’s Bill; (C) = Committee Bill; (P) = Private Bill; (H) = Hybrid Bill.
Questions and Answers
Date answered:
1 June 2023
S6W-17738
While disruptions in medicine supply can occur, they are often short in nature.
Questions and Answers
Date answered:
8 March 2023
S6W-15266
The Scottish Government is working to ensure an overarching approach for advanced therapy medicinal products (ATMPs) is in place in order to facilitate a ‘once for Scotland’ approach, where possible.
Committee reports
Date published:
30 June 2020
Supply and demand for medicines - Comprehensive reviews of prescriptions are not routinely taking place
Comprehensive reviews of prescriptions are not routinely taking place
Several reasons were outlined to us as to why reviews may not be taking place—
A reluctance to change medicines, both on the part of the patient and the prescriber; and
Resources required to undertake reviews, including GP time and the pharmacotherapy aspects of the GMS contract.
Committee reports
Date published:
30 June 2020
Supply and demand for medicines - Patients' Views
Patients' Views
The need for open conversations with patients on their medicines was emphasised throughout the inquiry, including on whether or not to change their prescriptions and prescription regimes.
Last updated:
16 February 2026
BB20260217
Members are advised to lodge amendments in good time before the beginning of a Stage and as early as possible during the day. (G) = Government Bill; (M) = Member’s Bill; (C) = Committee Bill; (P) = Private Bill; (H) = Hybrid Bill.
